Cas:142078-42-0 1,3a-dihydropyrrolo[3,2-c]pyridin-4-one manufacturer & supplier

We serve Chemical Name:1,3a-dihydropyrrolo[3,2-c]pyridin-4-one CAS:142078-42-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

1,3a-dihydropyrrolo[3,2-c]pyridin-4-one

Chemical Name:1,3a-dihydropyrrolo[3,2-c]pyridin-4-one
CAS.NO:142078-42-0
Synonyms:1,3a-dihydropyrrolo[3,2-c]pyridin-4-one
Molecular Formula:C7H6N2O
Molecular Weight:134.13500
HS Code:2933990090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:41.46000
Exact Mass:134.04800
LogP:

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 1,3a-dihydropyrrolo[3,2-c]pyridin-4-one chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1,3a-dihydropyrrolo[3,2-c]pyridin-4-one physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1,3a-dihydropyrrolo[3,2-c]pyridin-4-one Use and application,1,3a-dihydropyrrolo[3,2-c]pyridin-4-one technical grade,usp/ep/jp grade.


Related News: Britons being brought from Wuhan to the UK are being placed in quarantine at Arrowe Park Hospital in the Wirral, northwest England, Raab said. 1,3a-dihydropyrrolo[3,2-c]pyridin-4-one manufacturer Looking after their staff: Airlines are under pressure from their staff, who obviously want to protect themselves. 1,3a-dihydropyrrolo[3,2-c]pyridin-4-one supplier Looking after their staff: Airlines are under pressure from their staff, who obviously want to protect themselves. 1,3a-dihydropyrrolo[3,2-c]pyridin-4-one vendor Looking after their staff: Airlines are under pressure from their staff, who obviously want to protect themselves. 1,3a-dihydropyrrolo[3,2-c]pyridin-4-one factory Darzalex does have another regimen approved for the same myeloma population. Darzalex combined with Takeda’s Velcade, melphalan and prednisone (VMP) reduced the risk of death by 40% in the phase 3 ALCYONE trial. But disease progression had already occurred in half of patients on the Darzalex-VMP combo after about three years of follow-up, a much shorter period than the five-year mark the Darzalex-Rd regimen is approaching.